Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab

Acta Dermato-Venereologica

Volumn 92, Issue 4, 2012, Pages 357-358

  Inzinger, Martin ^a   Weger, Wolfgang ^a   Salmhofer, Wolfgang ^a   Wolf, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; METHOTREXATE; USTEKINUMAB;

ADULT; CASE REPORT; CHRONIC DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INFORMED CONSENT; LETTER; LOADING DRUG DOSE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HUMANS; MALE; PSORIASIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84863456407     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1243     Document Type: Letter

References (5)

1. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160: 810-820.
2. Kimball AB, Gordon KB, Langley RG, Menter A, Char-tash EK, Valdes J. ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. ArchDermatol 2008; 144: 200-207.
3. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
4. Papp KA, Langely RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double blind, placebo-controlled trial (PHOENIX2). Lancet 2008; 371: 1675-1684.
5. Inzinger M, Heschl B, Weger W, Hofer A, Legat FJ, Gruber-Wackernagel A, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011; 165: 640-645.